Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
This PHASE3 trial investigates ADPKD and is currently completed. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) leads this study, which shows 11 recorded versions since 2013 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE3
-
Dec 2021 — Dec 2022 [monthly]
Completed PHASE3
▶ Show 6 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE3
-
Sep 2019 — Jan 2021 [monthly]
Completed PHASE3
-
Sep 2018 — Sep 2019 [monthly]
Completed PHASE3
Phase: NA → PHASE3
-
Jun 2018 — Sep 2018 [monthly]
Completed NA
-
Apr 2017 — Jun 2018 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Jan 2017 — Apr 2017 [monthly]
Active Not Recruiting NA
First recorded
Jul 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- University of Colorado, Denver
For direct contact, visit the study record on ClinicalTrials.gov .